Trial Profile
To evaluate the post treatment changes in computer extracted measurements of vessel tortuosity between non small cell lung cancer patients who do and do not respond to Nivolumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Jun 2017 Results (n=50) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2017 Results (n=61) predicting response to nivolumab immunotherapy presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 New trial record